Adalimumab ELISA Kit (ab237641)
Key features and details
- Sensitivity: 10 ng/ml
- Range: 30 ng/ml - 1000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Quantitative
- Reacts with: Human
Overview
-
Product name
Adalimumab ELISA Kit
See all Adalimumab kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15% -
Sample type
Serum, Plasma -
Assay type
Quantitative -
Sensitivity
10 ng/ml -
Range
30 ng/ml - 1000 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 85% - 115% -
Assay duration
Multiple steps standard assay -
Species reactivity
Reacts with: Human -
Product overview
Note: Adalimumab ELISA kit ab237641 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Adalimumab in the sample or standard. Results of samples can be determined directly using the standard curve.
-
Notes
This product is manufactured by BioVision, an Abcam company and was previously called E4372 BioSim™ Adalimumab (Human) ELISA Kit. E4372-100 is the same size as the 96 test size of ab237641.
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 96 tests Adalimumab Standard S1 1 x 1ml Adalimumab Standard S2 1 x 1ml Adalimumab Standard S3 1 x 1ml Adalimumab Standard S4 1 x 1ml Adalimumab Standard S5 1 x 1ml Adalimumab Standard S6 1 x 1ml Adalimumab Standard S7 1 x 1ml Assay Buffer 1 x 50ml HRP-conjugate Probe 1 x 12ml Micro ELISA Plate 1 unit Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash buffer (20X) 1 x 50ml -
Relevance
Adalimumab is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha (TNF-a) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab237641 has been referenced in 2 publications.
- Abramson A et al. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors. Nat Biotechnol 40:103-109 (2022). PubMed: 34462588
- Hassan LA et al. Evaluation of the pattern and kinetics of degradation of adalimumab using a stability-indicating orthogonal testing protocol. Biomed Chromatogr 33:e4676 (2019). ELISA . PubMed: 31389037